-

Agenus to Participate in September Investor Conferences

LEXINGTON, Mass.LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences:

  • 2023 Wells Fargo Healthcare Conference – Fireside chat presentation will be held in-person on Thursday, September 7th, 2023, at 11:00 a.m. ET in Boston, MA. A live webcast and replay will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.
  • Baird 2023 Global Healthcare Conference– Fireside chat presentation will be held in person on Tuesday, September 12th, 2023, at 4:20 p.m. ET, in New York, NY. This content is for Baird clients attending the conference. There will not be a webcast replay.
  • HC Wainwright 25th Annual Global Investment Conference – Fireside chat presentation will be held in-person on Wednesday, September 13th, 2023, at 11:00 a.m. ET, in New York, NY. A live webcast and replay will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

Contacts

Investor Contact
917-362-1370
investor@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

Agenus Inc.

NASDAQ:AGEN

Release Versions

Contacts

Investor Contact
917-362-1370
investor@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

More News From Agenus Inc.

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL). The expansion reflects increasing interest from treating oncologists worldwide seeking access to BOT+BAL for p...

Agenus to Host First 2026 Stakeholder Webcast

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET. The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus’ botensilimab and balstilimab (BOT+BAL) program entering 2026. The ses...

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capac...
Back to Newsroom